Probiotics in premature infants: focus on necrotising enterocolitis by Van Niekerk, E
S35
Review Article: Probiotics in premature infants: focus on necrotising enterocolitis
2011;24(3) SupplementS Afr J Clin Nutr
Van Niekerk, BScDietetics, MDietetics
Stellenbosch University
Correspondence to: Evette van Niekerk, evettev@sun.ac.za 
Probiotics in premature infants:  
focus on necrotising enterocolitis
Introduction
Necrotising enterocolitis (NEC) is predominantly seen in premature 
infants and is the leading cause of mortality and morbidity in 
neonatal intensive care units (NICU).1-3 NEC is rare in term infants, 
whereas in the preterm infant it begins at 10-15 days after birth.1 
It is characterized by bowel wall necrosis of various length and 
depth. NEC has an overall incidence of 2-5% in all premature infants 
and up to >10% in babies weighing less than 1 500 g at birth.4,5
Pathogenesis of necrotising enterocolitis 
Although research has been conducted, the pathogenesis of 
NEC has not yet been fully elucidated but it is considered to be a 
multi-factorial disease.6,7 The most common known risk factors 
are prematurity, enteral feeding, ischaemia, infective agents and 
bacterial colonization.4,5,7,8 Epidemiological studies have reported 
a strong association between prematurity and NEC because of 
the structural and functional gastrointestinal incompetence of 
prematurity. Premature babies also present with lower gastric acid 
and pepsin production and lower levels of protective mucus.4,9
The fetal gut is exposed to amniotic fluid containing hormones 
and peptides that may have a role in intestinal maturation and 
preparation for postnatal feeding. Preterm infants may not have 
completed this maturation process when they are initially fed. 
Preterm infants are unable to digest carbohydrates and proteins 
completely, leading to the production of organic acids, which may 
be harmful to the developing gut.9 Several studies have shown that 
formula-fed infants have a higher incidence of NEC compared to 
breast fed infants. Breast milk contains multiple factors that improve 
intestinal maturation. In addition, human milk provides passive 
immunity factors such as polymeric immunoglobulin A (IgA) and 
macrophages that have immune protective properties.4,9 
The premature infant may also be exposed to antibiotic treatment 
during this early life stage, which may alter the intestinal micro flora, 
facilitate colonisation of the gut by more pathogenic organisms, and 
activate the inflammatory cascade, leading to high expressions of 
pro-inflammatory mediators. The combination of these events is 
currently thought to lead to the manifestation of NEC.5 
Diagnostic criteria of NEC
NEC is diagnosed on clinical grounds and roentgenographic findings. 
The initial symptoms may be subtle and non-specific and include 
apnoea, irregular temperature and lethargy. The most common sign 
of NEC is abdominal distension, which may be accompanied by 
bilious vomiting and feeding intolerance with high gastric aspirates. 
Gross blood appears in the stool in 25-63% of cases whereas occult 
blood is present in 22-59%.1,4,6 Severe NEC presents with respiratory 
failure, rapid cardiovascular and haemodynamic collapse, and 
shock.4 An abdominal X-ray is the current investigation of choice 
to confirm the clinical diagnosis of NEC. The radiological signs in 
early NEC include dilated and tubular in appearance bowel loops. 
The pattern of pneumatosis intestinalis and portal venous gas is 
diagnostic of NEC.10 Bell et al described three Stages of NEC, with 
Stage 1 being suggestive, Stage 2 being definitive, and Stage 3 
being severe. Stage 1 is extremely non-specific and may reflect 
feeding intolerance, sepsis or gastrointestinal haemorrhage. These 
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signs may also simply be manifestations of severe prematurity. 
Stage 1 should not be considered as definitive NEC but is useful, 
primarily to alert the clinician to early signs that may predict the 
development of NEC. Stage 2 represents early definitive NEC, is 
usually diagnosed radiologically by the presence of pneumatosis 
intestinalis and/or portal venous gas. Stage 3 is indicative of more 
advanced disease and it is usually associated with major systemic 
signs such as shock, and bowel perforation. Stage 3 usually requires 
surgical intervention.1,3,11 
The role of probiotics in premature infant nutrition
The intestinal microbial community is obtained from the birth 
canal and from close parental contact after birth.12 In contrast, 
the preterm infants acquire colonizing bacteria from the intensive 
care environment rather than their mother’s vaginal canal and skin 
surface.13 These infants often also receive antibiotic treatment 
perinatally to prevent acute sepsis which may further alter the 
composition of intestinal bacteria. Moreover, preterm infants have 
delayed colonization with healthy bacteria, such as Lactobacillus and 
Bifidobacterium species, which may lead to decreased function of 
the gut microbial community and immune functions.13-19 
The administration of probiotic to this vulnerable population may, 
at least on theoretical grounds, be an effective way to change the 
gut colonization with the so called healthy bacteria. It has been 
suggested that introducing probiotics to preterm infants might be 
beneficial to avoid overgrowth of pathogenic organisms. Probiotic 
supplementation has also been proposed to increase feeding 
tolerance, decrease the amount of days until full feeds are reached 
and prevent nosocomial infections in preterm infants. Probiotics 
administration potentially competes with other organisms for 
binding sites and substrate in the bowel, which increases the 
production of anti-inflammatory cytokines, decreases the production 
of pro-inflammatory cytokines, reduces intestinal permeability, and 
enhances enteral nutrition.20
A recent meta-analysis of 11 randomized clinical trials that involved 
2 176 premature infants treated with oral probiotics concluded that 
there are significant benefits with regards to the use of probiotic 
supplements in reducing all-cause mortality and NEC in preterm 
neonates. Overall evidence indicates that additional placebo 
controlled trials are unnecessary, if a suitable probiotic product is 
available.21 The data from a recently updated systematic review 
was used to develop basic guidelines on the use of probiotics in 
preterm infants. These guidelines give some clarity on specific strain 
selection, probiotic dose and the duration of supplementation.22
Strain selection
Bifidobacteria and lactobacilli have been found to be the most 
promising probiotic cultures in preterm neonates.12,23,24 It is important 
to bear in mind that there are different mechanisms underlying the 
clinical benefits of probiotics and that such benefits are also strain-
specific. Bifidobacteria are the dominant strains in infancy, and the 
combination of lactobacilli and bifidobacteria is known to enhance 
the bifidogenic effect.12,25,26 Lactobacillus and Bifidobacterium 
produce acidic end products during their metabolism and in so doing 
they lower the pH of the intestinal environment and create a locally 
unfavourable setting for pathogens.  The literature indicates that 
Lactobacillus binds to mucins and intestinal epithelial cells, and may 
be able to reverse the permeability of the immature gut.27
It would also appear that the functionality of a multistrain or 
multispecies probiotic preparation could be more effective and more 
reliable than that of a monostrain probiotic.28-30 A high number of 
different probiotic strains is not, in itself, indicative of greater efficacy 
when compared to that containing a lower number of strains.31 The 
guidelines indicate that it would be sensible to use probiotic products 
that have been shown to be effective in randomized clinical trials.
Recommended dose
An optimal dosage is vital for any probiotic strain to survive and 
optimally colonize the intestinal tract. The concept of viability 
refers to the ability of the probiotic strain to survive and proliferate 
in ‘adequate’ numbers to benefit the host. Evidence indicates 
that to be functional, probiotics have to be viable and in adequate 
dosage levels, typically 106 to 107 colony-forming units (CFU)/g of 
product.28,32,33
Based on the median dose used in clinical trials in preterm 
neonates, it is suggested that a daily dose of 3 × 109 CFU/day may 
be appropriate for neonates with a gestational age of less than 
32 weeks. Currently, there are no data available regarding a dose 
beyond which the risk of probiotic complications will be high in 
extremely low birth weight (ELBW) neonates. Until such research 
is available it is recommended that the starting dose should be 
1.5 × 109 CFU/day for ELBW neonates until they reach enteral feeds 
of 50-60 ml/kg/day. Because neonates are often intolerant to large 
enteral volumes, the probiotic dose may be decreased by half. 34 The 
reduced dose is still expected to be beneficial.22
When to start administration
The importance of early bacterial colonization in preterm neonates 
has been well established.21 With this in mind, it is recommended 
that probiotic supplementation should be started as early as possible 
before pathogens colonize the gut or antibiotics destroy the existing 
beneficial organisms.12,23,35 The majority of the clinical trials started 
probiotic supplementation when enteral feeds were initiated. The 
earliest reported age at which supplementation was initiated was 
four hours of life.22 It is desirable that premature neonates should 
be clinically stable (no signs of sepsis or ileus) to ensure that gut 
function is optimal with minimal risk of intolerance or translocation. 
The optimal protocol for probiotic administration in ELBW neonates 
with intrauterine growth restriction needs to be confirmed.36
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